The Vertex Pharmaceuticals story

What drives the business

• Vertex's core business treats the underlying cause of cystic fibrosis, with its medicines used by nearly three quarters of the approximately 97,000 people with CF in the U.S., Europe, Australia and Canada.
• Its strategy is to follow established medicines with newer treatments, including once-daily ALYFTREK as the successor to TRIKAFTA, with ALYFTREK reimbursement reaching 25 countries in the quarter to June 2026.
• CASGEVY, developed through the collaboration with CRISPR, extends Vertex into sickle cell disease and transfusion-dependent beta thalassemia, and its expanded U.S. approval for children as young as 2 years adds approximately 5,500 potentially eligible patients.
• JOURNAVX is a non-opioid medicine for acute pain, with approximately 535,000 prescriptions filled in the quarter to June 2026 and approximately 260 million individuals in the U.S. having reimbursed access at the August 2026 release.
• The Crinetics agreement adds a proposed endocrine business around PALSONIFY, atumelnant and other pipeline assets, with Vertex expecting the transaction to become accretive to non-GAAP operating income in 2029.

What the price assumes

At $527.67 per share, the reverse DCF assumes free cash flow after stock pay grows 17.7% a year for ten years, using a 10.2% discount rate.

Vertex delivered 17.2% annual growth on that measure over the last 7 years, while the TenQ check sets a 10.6% bar by slowing that record halfway to 4%.

The price therefore assumes growth above both the historical record and the check's slower-growth benchmark, alongside a free cash flow yield of 2.8%.

Value VRTX on your own assumptions

What could change the story

• ALYFTREK serves the same CF population as TRIKAFTA, so a successful transition protects the franchise without itself reducing dependence on cystic fibrosis.
• Commercial expansion carries costs: combined GAAP research, acquired research and administrative expenses rose to $1.6 billion in the quarter to June 2026 from $1.4 billion a year earlier, primarily to support JOURNAVX and the renal business.
• Revenue growth of 10.2% over the last twelve months was below the 10.4% annual pace over the last three years, failing TenQ's acceleration check despite rapid growth from the smaller launches.
• The approximately $10.0 billion Crinetics transaction is a substantial commitment against $13.6 billion of cash, cash equivalents and total marketable securities at June 30, 2026, and remains subject to closing conditions and integration execution.

What to watch next

• Vertex's raised 2026 revenue guidance of $13.1 billion to $13.2 billion includes $500 million or more from CASGEVY and JOURNAVX and approximately 150 basis points of growth from foreign exchange, net of hedging.
• Subsequent releases will show whether JOURNAVX prescription growth and CASGEVY patient infusions translate expanded reimbursement and eligibility into revenue.
• The FDA's November 30, 2026 action date for povetacicept is the next major milestone for establishing Vertex's commercial kidney disease business.
• Vertex anticipates closing Crinetics in the third quarter of 2026 and issuing updated guidance afterward, which will clarify the transaction's effect on spending and revenue.

Sources

• Vertex Pharmaceuticals's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The VRTX stock report, for every figure and check